New HPV approved after international phase 2/3 trial involving Moffitt Cancer Center

February 20, 2015

TAMPA, Fla. - Approximately 12,000 women are diagnosed with cervical cancer each year in the United States and another 4,000 die annually from the disease. However, most cervical cancers are preventable through immunization against the human papillomavirus (HPV). A pivotal international phase 2/3 clinical trial involving Moffitt Cancer Center faculty demonstrated that vaccination with Gardasil 9 protects against nine HPV types, seven of which cause most cases of cervical, vulvar, and vaginal disease. The trial data indicate that if populations are vaccinated with Gardasil 9 approximately 90 percent of all cervical cancers worldwide can be prevented.

HPV is the most common sexually transmitted virus. The virus is typically cleared by a person's own immune system within two years, resulting in no lasting health concerns. However, in some cases, HPV can lead to significant health problems, including genital warts and cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers. There are no clinically approved tests to distinguish those who will clear the virus from those who are at high risk of developing cancer.

A large, randomized, international phase 2/3 trial was initiated to compare the safety and efficacy of Gardasil 9 with Gardasil in more than 14,200 women, ages 16 to 26. Gardasil 9 was 97 percent effective at preventing high-grade cervical, vulvar and vaginal disease caused by HPV 31, 33, 45, 52 and 58, and was equally effective at preventing disease induced by HPV 6, 11, 16 and 18. Each case of high-grade disease that occurred in patients vaccinated with Gardasil 9 occurred in those who were already infected with HPV before they completed the study. This underlines "the importance of early vaccination prior to HPV exposure," said Giuliano. "More importantly, the vaccine was found to be safe with no significant vaccine-associated health concerns."

The vaccine trial results were published today in the New England Journal of Medicine, and the trial was funded by Merck & Co., Inc.

Until late 2014, there were two vaccines available to protect against as many as four HPV types - 6, 11, 16 and 18. The vaccines protect against 70 percent of HPVs that cause cervical cancer and also significantly reduce the risks of other types of cancer and genital warts. However, researchers have been trying to narrow the gap and completely eliminate any risk of HPV-induced disease. In December 2014, the Food and Drug Administration approved Gardasil 9, a vaccine that protects against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). According to Anna R. Giuliano, Ph.D., director of the Center for Infection Research in Cancer (CIRC) at Moffitt, Gardasil 9 "offers the potential to increase overall cervical cancer prevention from 70 to 90 percent, nearly eliminating this cancer from our communities."
-end-
About Moffitt Cancer Center:

Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's excellence in research and its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report's "Best Hospitals" for cancer since 1999. With more than 4,500 employees, Moffitt has an economic impact on Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.

H. Lee Moffitt Cancer Center & Research Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.